Table 2.
Comparison of clinicopathologic characteristics according to duration of DRFS for relapsed patients (n=122)
DRFS, distant relapse free survival; SD, standard deviation; HR, hormone receptor; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer; IDC, invasive ductal carcinoma; PFSR, progression free survival rate; OSR, overall survival rate. a)Extensive bone metastases,≥10 bones involvement with or without bone destruction soft tissue formation, b)Skeletal events, associated with bone metastases as pain, fracture, and limit of motion.
